Early cancer detection startup Craif raises $22M

Craif, an AI-powered startup spun from Nagoya University, raised $22 million in Series C funding to expand its U.S.-market presence and advance its miRNA-based cancer detection software, offering a non-invasive urine test for early diagnosis. With a valuation under $100 million after this round led by X&KSK and Unreasonable Group, the startup aims to scale its product, currently generating revenue in Japan through clinics and direct-to-consumer sales, into the U.S., targeting FDA approval by 2029.